Lupin gets USFDA nod for Diclofenac capsules' generic version

Image
Press Trust of India New Delhi
Last Updated : Dec 06 2016 | 1:13 PM IST
Pharma major Lupin today said it has received tentative approval for its generic version of Diclofenac capsules, used in pain management of osteoarthritis, from US health regulator USFDA.
The approval is for multiple strengths of 18 mg and 35 mg, a company statement said.
Lupins Diclofenac capsules are generic versions of Iroko Pharmaceuticals LLC's Zorvolex capsules of 18 mg and 35 MG, it added.
The capsules are indicated for management of mild to moderate acute pain and management of osteoarthritis pain.
Citing IMS MAT September 2016 data, Lupin said Zorvolex capsules had sales of USD 39.6 million in the US market.
Lupin has 139 product filings pending approval with the USFDA. Cumulative filings with the USFDA now stand at 341 with the company having received approvals for 202 products, the company added.
Shares of Lupin Ltd were trading 0.06 per cent down at Rs 1,535.70 apiece on BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 06 2016 | 1:13 PM IST

Next Story